Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer

Tresoldi, Alberto; Sburlati, L; Rodari, Marcello; Schinkelshoek, Mink S.; Perrino, Michela; Leo, Simone De; Montefusco, Laura; Colombo, Paolo; Arosio, Maura; Lania, Andrea; Fugazzola, Laura; Chiti, Arturo

doi:10.1007/s40618-014-0088-3

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is a trend toward higher ablation rates with higher activities, similar rates of successful remnant ablation have been reported using activities ranged from 30 to 100 mCi of 131 I [58][59][60]. A randomized study using preparation with rhTSH showed that ablation rates were comparable between 50 and 100 mCi [61].…”

Section: Activity Of 131 I To Be Employed For Postsurgical Thyroid Rementioning

confidence: 72%

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Castagna

Cantara

Pacini

2016

J Endocrinol Invest

View full text Add to dashboard Cite

Radioactive iodine therapy is administered to patients with differentiated thyroid cancer (DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with metastatic disease, for curative or palliative treatment. In past years, thyroid remnant ablation was indicated in almost every patient with a diagnosis of DTC. Nowadays, careful revision of patients' outcome has introduced the concept of risk-based selection of patients candidate to thyroid remnant ablation. The present review aims to underline the indications for thyroid remnant ablation and to address methodologies to be employed.

show abstract

Section: Activity Of 131 I To Be Employed For Postsurgical Thyroid Rementioning

confidence: 72%

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Castagna

Cantara

Pacini

2016

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…yroid tumors are derived from two different cell groups, parafollicular cells and follicular cells, which are basically divided into differentiated carcinomas, poorly differentiated carcinomas, and undifferentiated carcinomas [20]. yroid cancer differentiated from cells, accounting for about 90%, is basically divided into papillary or follicular shape.…”

Section: Pathogenesis Of Yroid Cancermentioning

confidence: 99%

Clinical Study of Virtual Reality Augmented Technology Combined with Contrast-Enhanced Ultrasound in the Assessment of Thyroid Cancer

Liu

Cheng

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Thyroid cancer has become the most common malignant tumor in the endocrine system, and its global incidence has been showing an upward trend. The diagnosis methods of thyroid cancer include ultrasound, fine-needle aspiration cytology, and neck CT, but the single ultrasound feature cannot simultaneously take into account the sensitivity and specificity of more than 85% when diagnosing thyroid cancer. The development of virtual technology can significantly improve the diagnosis of the thyroid gland. Based on this, this article proposes a clinical study of virtual reality technology combined with contrast-enhanced ultrasound in the assessment of thyroid cancer. This article uses a variety of methods, such as literature method, mathematical statistics, and experimental research, in-depth study of the theoretical cornerstones of virtual reality augmented technology, the application status of ultrasound contrast technology, and so on. And a fuzzy mean clustering algorithm was proposed to identify ultrasound images. Then, a clinical experiment of virtual reality augmented technology combined with contrast-enhanced ultrasound was designed to evaluate thyroid cancer, which included comparison of contrast-enhanced ultrasound signs, analysis of enhancement results, multifactor logistic analysis, and diagnostic efficacy analysis of ultrasound signs. The combined application of virtual reality augmented technology and contrast-enhanced ultrasound in the study of thyroid cancer has a sensitivity and specificity exceeding 85% as the diagnosis boundary changes, and the accuracy of the combined diagnosis is relatively high.

show abstract

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review

Ansari

Rezaei‐Tavirani

2022

Iran J Pharm Res

View full text Add to dashboard Cite

: The determination of radioiodine remnant ablation (RRA) dosage in post-operation thyroid residual tissues resection has been largely subject of discussion, yet no concise conclusion is released through systematic review studies. In this study, we conducted a systematic review of comparative experiments to evaluate and compare the efficacy of different prescribed dosages of radioiodine in post-op thyroid residual tissues resection among low, intermediate, and high-risk patients to approve the common method. Using automated searches, studies were collected from PUBMED, GOOGLE SCHOLAR, ELSEVIER, SCOPUS, and UPTODATE, all until April 2021. Alongside the aforementioned sources, comparative experiments were added in for further investigation. Overall, 4000 patients with papillary thyroid cancer, differentiated thyroid carcinoma (DTC), metastasized and non-metastasized thyroid cancer took part in twenty-one trials are assessed. We discovered no significant difference in successful thyroid residual tissues excision between low-activity and high-activity radioiodine treatment in people with low and intermediate risk. In these individuals, there was no significant difference between the high therapeutic dose of 3700 MBq and the lesser dose of 1850 MBq for RRA. However, high-dose treatment usually yielded superior results. Low activity RRA causes fewer adverse effects in metastasis-free patients than high-activity 3.7 GBq. There was no significant therapeutic difference regarding treatment efficacy in patients with low and moderate risks. However, in patients with high-risk status, applying a high-dose regimen of RRA produced a significantly better response.

show abstract

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer

Cited by 3 publications

References 29 publications

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Clinical Study of Virtual Reality Augmented Technology Combined with Contrast-Enhanced Ultrasound in the Assessment of Thyroid Cancer

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review

Contact Info

Product

Resources

About